
Sign up to save your podcasts
Or


Six verified stories from this week, in plain English, with the honest caveats left in.
The GLP-1 eye warning, in proportion. On 9 November the United States Food and Drug Administration required every GLP-1 receptor agonist to add NAION, a rare form of sudden painless vision loss in one eye, to the Warnings and Precautions section of its label. That covers semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide and orforglipron. The numbers deserve proportion. Across 126 clinical trials covering 134,253 patients there were 15 probable cases, 10 on a GLP-1 and 5 on placebo, which works out to 6.4 cases per 100,000 person years against 3.8. In real world data, GLP-1 starters had a higher rate than people starting a DPP-4 inhibitor, hazard ratio 1.43, barely clearing significance, and no significant difference against SGLT2 inhibitors. The regulator used the word potential, animal studies found no mechanism, and people on these drugs already carry the risk factors for optic nerve damage. If you lose vision suddenly and painlessly in one eye, seek help the same day, and do not stop your medication on your own.
A world first for type 1 diabetes. On 14 November, World Diabetes Day, the World Health Organization published its first ever guideline on diagnosing and managing type 1 diabetes in adults. It recommends multiple daily insulin injections adjusted to blood glucose, names human insulin as an appropriate and effective option, and recommends regular monitoring, with urine glucose testing considered where no other testing exists. About 9.5 million people were living with type 1 diabetes worldwide in 2025, with roughly 500,000 newly diagnosed. The caveat: a guideline does not by itself put insulin in a pharmacy.
A pill that improved sleep apnea. Published in JAMA on 9 November, two phase 3 trials of orforglipron in 712 adults with moderate to severe obstructive sleep apnea and excess weight. Over 52 weeks, breathing interruptions fell by about 18 events an hour on the tablet against 4.5 on placebo in people not using a breathing machine, and about 17 against 5 in those already using one. Weight loss was around 10 percent. Caveat: stomach side effects affected roughly 7 in 10 people, follow-up was one year, and nothing here shows it replaces a breathing machine.
A new kind of blood thinner for stroke. Also on 9 November, the FDA approved asundexian, sold as Sunharbo, the first factor XIa inhibitor, for adults after a recent non-cardioembolic ischemic stroke or high risk TIA who are already on antiplatelet therapy. In OCEANIC-STROKE it cut ischemic strokes by about 26 percent in relative terms and about 2 percentage points in absolute terms over two years, without an increase in major bleeding. Caveat: the absolute benefit is modest, it is not approved for atrial fibrillation, and the list price is around 750 dollars a month.
A safety result, not a victory lap. In The Lancet on 9 November, SYNCHRONIZE-CVOT tested survodutide in 5,530 adults with obesity or overweight plus cardiovascular disease, kidney disease or risk factors. It met its cardiovascular safety endpoint, with weight loss up to about 13.7 percent at 72 weeks against 2 percent on placebo. The caveat matters: the trial was designed to rule out harm, not to prove heart benefit, and the confidence interval is too wide to tell those apart. About 1 in 5 stopped because of stomach side effects, and the drug is not approved anywhere yet.
A tubeless insulin pump. On 13 November the FDA cleared a tubeless cartridge and infusion set for the Tandem Mobi, so the same pump can be worn with or without tubing for up to seven days. Caveat: this is a hardware clearance, not new outcome data, and it is not expected to be available until the first half of 2027.
The one habit to take away: if you live with diabetes, book a dilated eye examination and keep it on a yearly rhythm. Most sight threatening diabetic eye disease causes no symptoms until it is advanced.
One reminder. This is general education, not personal medical advice. Please talk to your own clinician about your care.
Topics: diabetes, type 1 diabetes, type 2 diabetes, GLP-1, semaglutide, tirzepatide, orforglipron, NAION, vision loss, eye health, diabetic retinopathy, obesity, sleep apnea, stroke, insulin pump, FDA, World Health Organization, medical news
This week: the United States approves a basal insulin you inject once a week, Roche reports striking mid stage numbers for a new dual hormone drug, Danish registry data show the cancer gap in type two diabetes is widening, a review of nearly nine million adults puts figures on ultra processed food, and the United States records its worst measles year since elimination.
General education, not personal medical advice. Please talk to your own clinician about your care.
This week: how quickly weight returns after stopping semaglutide or tirzepatide, why a borderline normal haemoglobin may deserve a closer look, twelve month results for automated insulin delivery in type 1 diabetes, why the testosterone dose matters for heart rhythm, and what two million people can and cannot tell us about drinks and mood.
In this episode.
Weight regain after stopping a GLP-1, from a pooled analysis of six randomised trials in Endocrinology, Diabetes and Metabolism.
Borderline low haemoglobin and mortality, from half a million adults in the UK Biobank, published in Annals of Internal Medicine.
Automated insulin delivery at twelve months in adults with type 1 diabetes.
Testosterone and atrial fibrillation, and why the target level matters, from the Journal of the Endocrine Society.
Drinks, depression and anxiety, from fifty-nine studies covering more than two million people.
Every story carries its caveat in the episode. Correlation is not causation, and preliminary findings are flagged as preliminary.
This is general education, not personal medical advice. Please talk to your own clinician about your care.
This week: a large trial finds statins cut heart attacks and strokes in healthy over seventies but do not prevent dementia or disability, a Scandinavian study of more than 280,000 people pins down who is most at risk of ketoacidosis on flozin medicines, semaglutide and tirzepatide enter the European heart failure guidelines, immune cells appear to remember obesity for years, and four medical bodies issue joint autumn vaccine advice.
statins, atorvastatin, STAREE trial, primary prevention, healthy ageing, SGLT2 inhibitors, flozins, diabetic ketoacidosis, sick day rules, type 2 diabetes, heart failure, ESC guidelines, semaglutide, tirzepatide, GLP-1, obesity, weight loss, immune system, flu vaccine, COVID vaccine, RSV
This week in plain English: the first wearable that tracks glucose and ketones together, the STAREE trial on statins for healthy over 70s, why missed blood pressure pills erase their benefit, the first RAS targeted drug for pancreatic cancer, and new guidelines on cardiac rehab.
Source:
The FDA has authorized Libre Duo, a wearable sensor designed to monitor glucose and ketones continuously for people with diabetes aged two years and older.
This Medical News Update explains how the system works, why rising ketones matter, its potential role in detecting diabetic ketoacidosis risk, and the important limitations patients and caregivers should understand. Continuous monitoring supports, but does not replace, a written sick-day plan, backup ketone testing, or urgent medical care when warning symptoms develop.
Read the full patient-friendly article:
https://livingdiabetes.com/fda-libre-duo-continuous-glucose-ketone-monitoring/
For general education only. This episode does not replace individualized medical advice, product instructions, or emergency care.
This week, a nationwide Cyclospora outbreak tied to fast food lettuce, the first pill form of a powerful cholesterol drug, new data on activity levels for people on GLP-1 medications, a possible link between hormone exposure and thyroid cancer, and an update on the Ebola outbreak in Central Africa. Plain English, no hype.
The FDA warns TRUE METRIX meters can show one E-5 code for two very different problems. Don't stop testing — but arrange a backup meter when you can.
A safety alert for anyone using a TRUE METRIX blood glucose meter. The FDA has flagged a serious problem — the same "E-5" error code can mean either dangerously high glucose OR a simple test strip error. Those need opposite responses, and getting it wrong can be dangerous. We explain what the FDA is recommending and, importantly, what NOT to do.
In this episode:
• Which meters are affected — TRUE METRIX, AIR, GO, PRO, and cobranded versions
• Why one error code for two situations is a real safety risk
• The FDA's most important instruction — don't stop testing abruptly
• Who's at highest risk — people on intensive insulin or sulfonylureas
• How to switch to a backup testing method safely
• What to do if you see an E-5 error with symptoms
Key takeaway: If you use TRUE METRIX, arrange another testing method when you can — but keep monitoring until your backup is ready. If an E-5 error appears and you feel symptoms of high or low glucose, get help rather than guessing.
Disclaimer: This podcast is for general education only. It is not medical advice. Always consult your diabetes care team. Severe symptoms — confusion, loss of consciousness, seizure, repeated vomiting, or signs of diabetic ketoacidosis — require urgent medical care.
Show notes / sources:
#TrueMetrix #GlucoseMeter #BloodGlucose #DiabetesTech #FDA #DiabetesSafety #Trividia #BGM #MedicalNewsUpdate
The FDA posted an Omnipod correction — some Pods may under-deliver insulin. Not every Pod is affected. Check your lot numbers and keep a backup plan.
If you use an Omnipod insulin pump, here's an important safety notice — explained calmly. On May 26, 2026, the FDA posted a voluntary Medical Device Correction from Insulet because certain Pods may leak insulin and deliver less than intended. This is a correction, not a blanket recall — most Pods aren't affected — but everyone using Omnipod should check their lot numbers and make sure they have a safe insulin backup.
In this episode:
• Which products are in scope — specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros
• What "insulin under-delivery" means and why it can raise blood sugar
• The Class I recall entry for Omnipod 5 ACE Pump Pods
• Warning signs while wearing a Pod — wetness, insulin smell, unexplained highs
• Why you should never stop insulin without an alternative plan in place
• The DKA symptoms that mean it's time to get urgent help
Key takeaway: Check your Pod lot numbers on the official Omnipod/Insulet correction page. If yours are affected, stop using them and get free replacements — but do NOT stop insulin without a backup plan from your diabetes team.
Disclaimer: This podcast is for general education only. It is not medical advice. Always consult your diabetes care team. Seek urgent care if high glucose comes with symptoms that could suggest diabetic ketoacidosis.
Show notes / sources:
#Omnipod #InsulinPump #Insulet #DiabetesTech #Type1Diabetes #DiabetesSafety #FDA #InsulinDelivery #MedicalNewsUpdate
Two lots of Dexcom G7 sensors were stolen before destruction and resold. Check lot numbers 1725204004 and 1725069002. Here's what to do.
A safety alert for anyone using a Dexcom G7 continuous glucose monitor. On May 26, 2026, Dexcom revealed that sensors marked for destruction were stolen and resold through unauthorized channels. This is NOT a warning about every G7 sensor — it affects two specific lot numbers. We walk through exactly what to check and what to do.
In this episode:
• The two affected lot numbers — 1725204004 and 1725069002 — read slowly so you can check
• Why one lot has a sterilization concern (skin infection risk) and the other a higher failure rate
• How to find the lot number on your sensor packaging
• What to do if you have an affected sensor — and how to get a free replacement
• Why this is NOT a blanket recall of all G7 sensors
Key takeaway: Check your Dexcom G7 packaging against lot numbers 1725204004 and 1725069002. If yours matches, don't use it — contact Dexcom for a replacement and use a backup glucose check if needed. Don't change any medication based on this news alone.
Disclaimer: This podcast is for general education only. It is not medical advice. Always consult your diabetes care team. If you have signs of severe high or low glucose, diabetic ketoacidosis, or a serious skin infection, seek urgent care.
Show notes / sources:
#Dexcom #DexcomG7 #CGM #DiabetesTech #ContinuousGlucoseMonitor #Recall #DiabetesSafety #Type1Diabetes #MedicalNewsUpdate
From the publisher's feed
Welcome to "Medical News Updates," the go-to channel for anyone eager to understand complex medical news in a straightforward, simplified manner. Our mission is to break down the latest health…
What We Offer:
Why Subscribe?